In today’s briefing:
- Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst
- EQD | Where to BUY the KOSPI On The Upcoming Pullback
Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst
- Alteogen Inc (196170 KS) has modified the existing license agreement with Merck. Revised terms of the agreement grant Merck exclusive global right to ALT-B4 for a specific product group, pembrolizumab.
- Under the terms of the revised agreement, Alteogen will receive an upfront payment of $20M from Merck. Alteogen will also receive additional milestone payment of up to $432M.
- Approval of Alteogen’s first proprietary product, Tergase (expected in early 2024) will be the next major catalyst for the company.
EQD | Where to BUY the KOSPI On The Upcoming Pullback
- The KOSPI 200 INDEX has been rallying since January 2022, roughly up +22.5%, the rally can continue, but soon there could be a pullback, possibly this coming week.
- If the index falls from its current highs, where are the best support levels to go LONG again?
- The price area between 355 and 345 is where the index could find support and resume the uptrend.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
